Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Laura Orlando, Evaristo Maiello, Michele Orditura, Anna Diana, Giuliano Antoniol, Maria Grazia Morritti, Michele Aieta, Mariangela Ciccarese, Salvatore Pisconti, Roberto Bordonaro, Antonio Russo, Antonio Febbraro, Paola Schiavone, Annamaria Quaranta, Chiara Caliolo, Dario Loparco, Margherita Cinefra, Giuseppe Colucci, Saverio Cinieri
BACKGROUND: Optimizing chemotherapy to achieve disease and symptoms control is a noteworthy purpose in advanced breast cancer (ABC). We reported the activity and quality of life of a phase II study, comparing metronomic regimen with standard schedule as first line chemotherapy for ABC. METHODS: Patients with HER2 negative ABC were randomized to non-pegylated liposomal doxorubicin (NPLD, 60 mg/m2 every 3 weeks) and cyclophosphamide (CTX, 600 mg/m2 every 3 weeks) (Arm A) or NPLD (20 mg/m2 day, on day 1, 8 and 15 every 4 weeks) and metronomic daily oral CTX 50 mg (ARM B)...
April 5, 2024: Breast: Official Journal of the European Society of Mastology
#2
JOURNAL ARTICLE
Haizhu Chen, Xiujuan Gui, Ziwei Zhou, Fengxi Su, Chang Gong, Shunrong Li, Wei Wu, Nanyan Rao, Qiang Liu, Herui Yao
INTRODUCTION: The impact of distinct estrogen receptor (ER) and progesterone receptor (PR) expression patterns on tumor behavior and treatment outcomes within HER2-positive breast cancer is not fully explored. This study aimed to comprehensively examine the clinical differences among patients with HER2-positive breast cancer harboring distinct ER and PR expression patterns in the neoadjuvant setting. METHODS: This retrospective analysis included 871 HER2-positive breast patients treated with neoadjuvant therapy at our hospital between 2011 and 2022...
April 11, 2024: Breast: Official Journal of the European Society of Mastology
#3
JOURNAL ARTICLE
Felippe Lazar Neto, Marina Acevedo Zarzar de Melo, Cassio Murilo Trovo Hidalgo Filho, Maria Cecília Mathias-Machado, Laura Testa, Alessandro Gonçalves Campolina
BACKGROUND: Breast cancer (BC) is the most incident tumor and, consequently, any new intervention can potentially promote a considerable budget impact if incorporated. Cost-effectiveness (CE) studies assist in the decision-making process but may be influenced by the country's perspective of analysis and pharmaceutical industry funding. METHODS: A systematic review of Medline, Scopus, and Web of Science from January 1st, 2012 to July 8th, 2022 was conducted to identify CE studies of tumor-targeted systemic-therapies for advanced BC...
April 5, 2024: Breast: Official Journal of the European Society of Mastology
#4
REVIEW
Joey Z Gu, Grayson L Baird, Antonio Escamilla Guevara, Young-Jin Sohn, Melis Lydston, Christopher Doyle, Sarah E A Tevis, Randy C Miles
BACKGROUND: Online patient education materials (OPEMs) are an increasingly popular resource for women seeking information about breast cancer. The AMA recommends written patient material to be at or below a 6th grade level to meet the general public's health literacy. Metrics such as quality, understandability, and actionability also heavily influence the usability of health information, and thus should be evaluated alongside readability. PURPOSE: A systematic review and meta-analysis was conducted to determine: 1) Average readability scores and reporting methodologies of breast cancer readability studies; and 2) Inclusion frequency of additional health literacy-associated metrics...
April 3, 2024: Breast: Official Journal of the European Society of Mastology
#5
REVIEW
Kleoniki Apostolidou, Eleni Zografos, Maria Alkistis Papatheodoridi, Oraianthi Fiste, Meletios Athanasios Dimopoulos, Flora Zagouri
Over the past few decades, first-line therapy for treating advanced and metastatic HR+/HER2-breast cancer has transformed due to the introduction of adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i). However, there is an unmet need for novel classes of endocrine therapy with superior efficacy to improve treatment outcomes and overcome CDK4/6i resistance. New generation selective estrogen receptor degraders (SERDs), orally administered and with higher bioavailability, could potentially be the novel compounds to meet this emerging need...
April 4, 2024: Breast: Official Journal of the European Society of Mastology
#6
JOURNAL ARTICLE
Sommer Agnew, Megan Crawford, Iain MacPherson, Victor Shiramizu, Leanne Fleming
BACKGROUND: When taken as prescribed, endocrine therapy is effective in reducing risk of recurrence and mortality in the treatment of patients with breast cancer. However, treatment side effects can act as a barrier to medication adherence. Existing research has not identified any specific side effects as consistent predictors of nonadherence. Our aim was to explore the influence of symptom clusters on self-reported adherence in patients with breast cancer. METHODS: A cross-sectional online survey was conducted, including patients with breast cancer currently or previously prescribed endocrine therapy (N = 1051)...
April 6, 2024: Breast: Official Journal of the European Society of Mastology
#7
JOURNAL ARTICLE
Josefien P van Olmen, Chaja F Jacobs, Sanne A L Bartels, Claudette E Loo, Joyce Sanders, Marie-Jeanne T F D Vrancken Peeters, Caroline A Drukker, Frederieke H van Duijnhoven, Marleen Kok
OBJECTIVE: This study aims to evaluate the response to and surgical benefits of neoadjuvant endocrine therapy (NET) in ER+/HER2-breast cancer patients who are clinically high risk, but genomic low risk according to the 70-gene signature (MammaPrint). METHODS: Patients with ER+/HER2-invasive breast cancer with a clinical high risk according to MINDACT, who had a genomic low risk according to the 70-gene signature and were treated with NET between 2015 and 2023 in our center, were retrospectively analyzed...
April 5, 2024: Breast: Official Journal of the European Society of Mastology
#8
JOURNAL ARTICLE
Richard Chou, Diana Tran, Joseph Descallar, Bin Jalaludin, Patsy S Soon
INTRODUCTION: Atypical or B3 lesions comprise a heterogeneous group of uncertain malignant potential. B3 lesions diagnosed on core biopsy are usually recommended for diagnostic open biopsy. Identifying factors which could allow conservative management of B3 lesions would be helpful in avoiding unnecessary surgery. The aim of this study was to identify the upgrade rate to malignancy for B3 core biopsy lesions and to compare characteristics of lesions which were malignant and benign at excision...
March 29, 2024: Breast: Official Journal of the European Society of Mastology
#9
JOURNAL ARTICLE
Petra Zemankova, Marta Cerna, Klara Horackova, Corinna Ernst, Jana Soukupova, Marianna Borecka, Britta Blümcke, Leona Cerna, Monika Cerna, Vaclava Curtisova, Tatana Dolezalova, Petra Duskova, Lenka Dvorakova, Lenka Foretova, Ondrej Havranek, Jan Hauke, Eric Hahnen, Miloslava Hodulova, Milena Hovhannisyan, Lucie Hruskova, Marketa Janatova, Maria Janikova, Sandra Jelinkova, Pavel Just, Marcela Kosarova, Monika Koudova, Vera Krutilkova, Eva Machackova, Katerina Matejkova, Renata Michalovska, Adela Misove, Petr Nehasil, Barbora Nemcova, Jan Novotny, Ales Panczak, Pavel Pesek, Ondrej Scheinost, Drahomira Springer, Barbora Stastna, Viktor Stranecky, Ivan Subrt, Spiros Tavandzis, Eva Tureckova, Kamila Vesela, Zdenka Vlckova, Michal Vocka, Barbara Wappenschmidt, Tomas Zima, Zdenek Kleibl, Petra Kleiblova
Germline CHEK2 pathogenic variants confer an increased risk of female breast cancer (FBC). Here we describe a recurrent germline intronic variant c.1009-118_1009-87delinsC, which showed a splice acceptor shift in RNA analysis, introducing a premature stop codon (p.Tyr337PhefsTer37). The variant was found in 21/10,204 (0.21%) Czech FBC patients compared to 1/3250 (0.03%) controls (p = 0.04) and in 4/3639 (0.11%) FBC patients from an independent German dataset. In addition, we found this variant in 5/2966 (0...
March 25, 2024: Breast: Official Journal of the European Society of Mastology
#10
REVIEW
Vincent Lavoue, Amélia Favier, Sophie Franck, Gérard Boutet, Anne-Sophie Azuar, Susie Brousse, François Golfier, Catherine Uzan, Charlotte Vaysse, Sébastien Molière, Martine Boisserie-Lacroix, Edith Kermarrec, Jean-Yves Seror, Yann Delpech, Élisabeth Luporsi, Christine M Maugard, Nicolas Taris, Nathalie Chabbert-Buffet, Jonathan Sabah, Khalid Alghamdi, Xavier Fritel, Carole Mathelin
UNLABELLED: Breast cancer is the most common female cancer in the world. Numerous studies have shown that the risk of metastatic disease increases with tumor volume. In this context, it is useful to assess whether the regular practice of formal breast self-examination (BSE) as opposed to breast awareness has an impact on the number of cancers diagnosed, their stage, the treatments used and mortality. DESIGN: The Commission of Senology (CS) of the Collège National de Gynécologie et Obstétrique Français (CNGOF) respected and followed the Grading of Recommendations Assessment, Development and Evaluation method to assess the quality of the evidence on which the recommendations were based...
January 3, 2024: Breast: Official Journal of the European Society of Mastology
#11
REVIEW
Ranjeeta Subedi, Nehmat Houssami, Carolyn Nickson, Anant Nepal, Denise Campbell, Michael David, Xue Qin Yu
PURPOSE: Shorter time from symptoms recognition to diagnosis and timely treatment would be expected to improve the survival of patients with breast cancer (BC). This review identifies and summarizes evidence on time to diagnosis and treatment, and associated factors to inform an improved BC care pathways in Low- and Middle-Income Countries (LMICs). METHODS: A systematic search was conducted in electronic databases including Medline, Embase, PsycINFO and Global Health, covering publications between January 1, 2010, and November 6, 2023...
March 18, 2024: Breast: Official Journal of the European Society of Mastology
#12
JOURNAL ARTICLE
John Loggie, Penelope J Barnes, Michael D Carter, Daniel Rayson, Gillian C Bethune
PURPOSE: It remains unclear whether patients with HER2-negative, low-estrogen receptor (ER-low)-positive early breast cancer (BC) benefit from Oncotype DX® (ODX) testing. METHODS: We conducted a retrospective review of cases referred for ODX testing over a seven-year period from a breast biomarker testing referral center (n = 854). For each case, we recorded the ODX Recurrence Score (RS) along with percentage of ER nuclear positivity and staining intensity on immunohistochemistry...
March 19, 2024: Breast: Official Journal of the European Society of Mastology
#13
JOURNAL ARTICLE
S M Vijayarajan, D Manoj Kumar, G Sudha, A Basi Reddy
This manuscript proposes thermal images using PCSAN-Net-DBOA Initially, the input images are engaged from the database for mastology research with infrared image (DMR-IR) dataset for breast cancer classification. The adaptive distorted Gaussian matched-filter (ADGMF) was used in removing noise and increasing the quality of infrared thermal images. Next, these preprocessed images are given into one-dimensional quantum integer wavelet S-transform (OQIWST) for extracting Grayscale statistic features like standard deviation, mean, variance, entropy, kurtosis, and skewness...
March 19, 2024: Microscopy Research and Technique
#14
JOURNAL ARTICLE
Federica Miglietta, Letizia Pontolillo, Carmine De Angelis, Roberta Caputo, Monica Marino, Emilio Bria, Rossana Di Rienzo, Annarita Verrazzo, Carlo Buonerba, Giampaolo Tortora, Giuseppe Di Lorenzo, Lucia Del Mastro, Mario Giuliano, Filippo Montemurro, Fabio Puglisi, Valentina Guarneri, Michelino De Laurentiis, Luca Scafuri, Grazia Arpino
BACKGROUND: The last years have seen unprecedented improvement in breast cancer (BC) survival rates. However, this entirely apply to female BC patients, since gender minorities (male, transgender/gender-diverse) are neglected in BC phase III registration clinical trials. METHODS: We conducted a scoping review of phase III clinical trials of agents with a current positioning within the therapeutic algorithms of BC. RESULTS: We selected 51 phase III trials...
March 9, 2024: Breast: Official Journal of the European Society of Mastology
#15
REVIEW
Sofia Re Mason, Melina L Willson, Sam J Egger, Jane Beith, Rachel F Dear, Annabel Goodwin
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with shorter survival and a higher likelihood of recurrence. In early TNBC, platinum chemotherapy has been shown to improve pathological complete response (pCR); however, its effect on long-term survival outcomes has not been fully elucidated. METHODS: Randomised controlled trials examining neoadjuvant or adjuvant platinum chemotherapy for early TNBC were included...
March 12, 2024: Breast: Official Journal of the European Society of Mastology
#16
REVIEW
Guillaume Parpex, Marie Ottaviani, Henri Lorphelin, Matthieu Mezzadri, Eva Marchand, Laurence Cahen-Doidy, Jean Louis Benifla, Cyrille Huchon, Camille Mimoun
BACKGROUND: Sentinel lymph node biopsy (SLNB) is commonly used in the surgical management of male breast cancer. Contrary to female breast cancer, limited data exist about its performance in male breast cancer. The objective of this systematic review and meta-analysis was to evaluate the SLNB accuracy in male breast cancer. METHODS: MEDLINE, EMBASE, Web of Science and The Cochrane Library were searched from January 1995 to April 2023 for studies evaluating the SLNB identification rate and false-negative rate in male breast cancer with negative preoperative axillary evaluation and primary surgery...
March 5, 2024: Breast: Official Journal of the European Society of Mastology
#17
JOURNAL ARTICLE
Patients' and doctors' views and experiences of the patient safety trajectory of breast cancer care.
Clara Forrest, Martin J O'Sullivan, Max Ryan, Colm O'Tuathaigh, Tara Jane Browne, Kathy Rock, Mary Jane O'Leary, Deirdre Madden, Seamus O'Reilly
INTRODUCTION: Successful breast cancer outcomes can be jeopardised by adverse events. Understanding and integrating patients' and doctors' perspectives into care trajectories could improve patient safety. This study assessed their views on, and experiences of, medical error and patient safety. METHODS: A cross-sectional, quantitative 20-40 item questionnaire for patients attending Cork University Hospital Cancer Centre and breast cancer doctors in the Republic of Ireland was developed...
February 29, 2024: Breast: Official Journal of the European Society of Mastology
#18
JOURNAL ARTICLE
Sherif Elawa, Ingemar Fredriksson, Ingrid Steinvall, Johan Zötterman, Simon Farnebo, Erik Tesselaar
The pathophysiological mechanism behind complications associated with postmastectomy radiotherapy (PMRT) and subsequent implant-based breast reconstruction are not completely understood. The aim of this study was to examine if there is a relationship between PMRT and microvascular perfusion and saturation in the skin after mastectomy and assess if there is impaired responsiveness to a topically applied vasodilator (Methyl nicotinate - MN). Skin microvascular perfusion and oxygenation >2 years after PMRT were measured using white light diffuse reflectance spectroscopy (DRS) and laser Doppler flowmetry (LDF) in the irradiated chest wall of 31 women with the contralateral breast as a control...
March 6, 2024: Breast: Official Journal of the European Society of Mastology
#19
REVIEW
Kavitha Däster, Ricardo Pardo Garcia, Yazan Masannat, Ashutosh Kothari
Oncoplastic breast surgery (OPS) has become an integral part of breast cancer surgery for both breast conservation and mastectomies. In recent years, the emphasis on early detection and the advances in systemic and locoregional therapy has improved prognosis leading to an increased focus on survivorship and quality of life issues including patients' short and long-term aesthetic appearance as a key part of the surgical management. There is a significant variation across Europe in the type of specialist performing breast cancer surgery and the provision of OPS as such...
February 29, 2024: Gland Surgery
#20
JOURNAL ARTICLE
Adri C Voogd, Zsófi Molnar, Joost Nederend, Robert-Jan Schipper, Luc J A Strobbe, Lucien E M Duijm
AIM: A false positive (FP) referral after screening mammography may influence a woman's likelihood to re-attend the screening program. The impact of having a FP result in the first or subsequent screening round on re-attendance after a FP result was investigated. In addition, we aimed to study differences in re-attendance rates between women who underwent non-invasive and invasive additional examinations as part of the diagnostic work-up following a FP referral. METHODS: A consecutive series of 13,597 women with a FP referral following biennial screening mammography in the south of the Netherlands between 2009 and 2019 was included...
February 27, 2024: Breast: Official Journal of the European Society of Mastology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
